Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 2Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 45Bortezomib 19Lenalidomide 18Calcium Dobesilate 18Melphalan 16Cyclophosphamide 11pomalidomide 10daratumumab 9elotuzumab 8carfilzomib 8pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone acetate 6fludarabine 5dexamethasone 21-phosphate 5Filgrastim 5venetoclax 4selinexor 4auricularum 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Whole-Body Irradiation 3Vorinostat 3Nivolumab 3Mycophenolic Acid 3Leukapheresis 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × Simvastatin × Clear all
NCT02971410 2018-07-02

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

Wake Forest University Health Sciences

Phase EARLY_PHASE1 Withdrawn
Plasma cell

Multiple Myeloma

NCT01332617 2017-12-29

Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

University of Louisville

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡